220741-66-2

Upstream product

• 51388-20-6 4-benzyloxyaniline hydrochloride 
• 71072-37-2 1-tert-butyl-carbonyl-4-piperidone 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 6373-46-2 p-benzyloxyaniline 
• 590-86-3 isovaleraldehyde 
• 220741-33-3 4-(4-benzyloxy-phenylamino)-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 220741-67-3 (4-benzyloxy-phenyl)-(3-methyl-butyl)-piperidin-4-yl-amine 
• 247116-65-0 Azepane-1-carboxylic acid ((S)-1-{4-[(4-benzyloxy-phenyl)-(3-methyl-butyl)-amino]-piperidine-1-carbonyl}-3-methyl-butyl)-amide 

Relevant academic research and scientific papers

Aniline derivatives as calcium channel blockers

The present invention provides compounds that block calcium channels having formula (I). The present invention also provides methods of using the compounds of formula (I) to treat stroke, cerebral ischemia, head trauma, or epilepsy and to pharmaceutical compositions that contain the compounds of formula (I).

Heterocyclic substituted aniline calcium channel blockers

The present invention provides compounds that block calcium channels having the Formula I shown below. STR1The present invention also provides methods of using the compounds of Formula I to treat stroke, cerebral ischemia, head trauma, epilepsy, asthma, amyotrophic lateral sclerosis, or pain and to pharmaceutical compositions that contain the compounds of Formula I.

Structure-activity relationship at the proximal phenyl group in a series of non-peptidyl N-type calcium channel antagonists

Selective N-Type Voltage Sensitive Calcium Channel (VSCC) antagonists have shown utility in several models of pain and ischemia. We report the structure-activity relationship at the proximal phenyl group in a series of non-peptidyl VSCC blockers.